Immunome, Inc. (IMNM) Income Statement
IMNM 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsIMNM revenue and net income
Where IMNM's revenue goes
2025Each bar shows an amount and its share of revenue. IMNM kept −3,060.0% of revenue as net income.
IMNM profit margins
IMNM growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −23.2% | +1.6% | — | — |
| Gross profit | −55.9% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
IMNM quarterly EPS vs estimates
Immunome beat the analyst EPS estimate in 3 of the last 8 quarters. Next report: November 5, 2026 (estimate $-0.68).
IMNM income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.9M | $9.0M | $14.0M | $6.6M | $0 | $0 | $0 | $0 |
| Cost of revenue | $3.0M | $2.1M | $728,000 | $631,000 | $755,000 | $755,000 | $615,000 | $521,000 |
| Gross profit | $4.0M | $9.0M | $14.0M | −$631,000 | −$755,000 | −$755,000 | −$615,000 | −$521,000 |
| Research & development | $174.3M | $129.5M | $23.1M | $23.3M | $14.1M | $7.5M | $8.8M | $6.9M |
| Sales, general & admin | $43.8M | $33.0M | $19.7M | $13.6M | $11.1M | $4.8M | $1.5M | $866,000 |
| Total operating expenses | $218.1M | $314.8M | $123.5M | $36.9M | $25.2M | $12.3M | $10.3M | $7.7M |
| Operating income | −$214.1M | −$305.8M | −$109.5M | −$36.9M | −$25.2M | −$12.3M | −$10.3M | −$7.7M |
| Interest income | $11.7M | $12.8M | $2.7M | $5,000 | — | $1,000 | $10,000 | $39,000 |
| Interest expense | — | — | — | $5,000 | $10,000 | $38,000 | $106,000 | $141,000 |
| Income before taxes | −$212.4M | −$293.0M | −$106.8M | −$36.9M | −$24.7M | −$17.8M | −$10.4M | −$7.8M |
| Income taxes | — | −$293.0M | $560,105 | $617,000 | −$242,000 | −$717,000 | $106,000 | $39,000 |
| Net income | −$212.4M | −$293.0M | −$106.8M | −$36.9M | −$24.7M | −$17.1M | −$10.6M | −$7.8M |
| EBITDA | −$209.4M | −$151.4M | −$28.0M | −$36.3M | −$23.9M | −$11.5M | −$9.7M | −$7.2M |
| EPS (diluted) | −$2.43 | −$4.73 | −$5.39 | −$3.09 | −$2.16 | −$8.44 | −$1.84 | −$7.84 |
| Gross margin | 57.4% | 100.0% | 100.0% | −9.5% | — | — | — | — |
| Operating margin | −3,084.8% | −3,382.4% | −781.4% | −556.8% | — | — | — | — |
| Net margin | −3,060.0% | −3,240.4% | −761.9% | −556.8% | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $4.0M | $2.9M | $2.7M | $2.9M | $2.4M | $1.0M | $3.8M | $3.6M |
| Cost of revenue | — | $753,000 | $776,000 | $49.2M | $720,000 | $726,000 | $595,000 | $571,000 | $673,000 | $263,000 | $257,000 | $166,000 |
| Gross profit | — | −$753,000 | −$776,000 | −$49.2M | $3.3M | $2.9M | $2.7M | $2.9M | $2.4M | $1.0M | $3.8M | $3.4M |
| Research & development | $59.9M | $46.4M | $60.8M | $49.2M | $40.5M | $36.9M | $47.9M | $37.2M | $29.1M | $15.4M | $9.6M | $3.8M |
| Sales, general & admin | $18.2M | $12.9M | $12.1M | $10.9M | $10.0M | $10.7M | $10.4M | $9.5M | $7.0M | $6.0M | $8.0M | $4.4M |
| Total operating expenses | $78.1M | $58.6M | $72.9M | $10.9M | $49.8M | $47.6M | $85.7M | $53.4M | $42.4M | $133.3M | $98.5M | $8.0M |
| Operating income | −$78.1M | −$59.3M | −$72.9M | −$60.1M | −$46.5M | −$44.6M | −$83.0M | −$50.5M | −$40.0M | −$132.3M | −$94.7M | −$4.6M |
| Interest income | $5.0M | $5.5M | $3.0M | $2.7M | $3.1M | $3.0M | $2.7M | $3.4M | $3.9M | $2.8M | $2.0M | $288,000 |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $201,000 | — |
| Income before taxes | −$73.1M | −$53.8M | −$69.9M | −$57.5M | −$43.4M | −$41.6M | −$80.2M | −$47.1M | −$36.1M | −$129.5M | −$92.6M | −$4.3M |
| Income taxes | — | — | — | — | — | — | — | — | — | −$1 | $367,000 | −$166,000 |
| Net income | −$73.1M | −$53.8M | −$69.9M | −$57.5M | −$43.4M | −$41.6M | −$80.2M | −$47.1M | −$36.1M | −$129.5M | −$92.6M | −$4.3M |
| EBITDA | −$72.0M | −$53.1M | −$69.1M | −$56.7M | −$42.7M | −$40.9M | −$55.0M | −$43.2M | −$33.0M | −$20.1M | −$13.6M | −$4.2M |
| EPS (diluted) | −$0.65 | −$0.48 | −$0.76 | −$0.65 | −$0.50 | −$0.52 | −$0.84 | −$0.78 | −$0.60 | −$2.51 | −$4.22 | −$0.36 |
| Gross margin | — | — | — | — | 82.1% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 95.3% |
| Operating margin | — | — | — | — | −1,157.6% | −1,525.5% | −3,030.3% | −1,736.2% | −1,692.4% | −12,857.0% | −2,473.9% | −130.0% |
| Net margin | — | — | — | — | −1,080.9% | −1,423.1% | −2,930.9% | −1,618.6% | −1,528.0% | −12,584.3% | −2,421.2% | −121.9% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in IMNM's financial statements (latest annual report filed March 3, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
IMNM financial results
In fiscal year 2025 (ended December 31, 2025), Immunome reported revenue of $6.9 million, down 23.2% from the year before. It had a net loss of $212.4 million, a net profit margin of −3,060.0%. Diluted earnings per share came to −$2.43.
See the IMNM stock overview for the latest quote and news, or the IMNM chart for price history and technical indicators.
IMNM income statement FAQ
What is Immunome's annual revenue?
Immunome reported total revenue of $6.9 million for fiscal year 2025, which ended on December 31, 2025. That was down 23.2% from $9.0 million the previous year.
Is Immunome profitable?
No. Immunome reported a net loss of $212.4 million in fiscal 2025, a net profit margin of −3,060.0%; its operating margin was −3,084.8%.
What is Immunome's gross margin?
Immunome's gross margin was 57.4% in fiscal 2025: for every $100 of revenue, Immunome kept $57 after the direct cost of its products and services.
How much does Immunome spend on research and development?
Immunome spent $174.3 million on research and development in fiscal 2025, 2,511.6% of revenue.
What are Immunome's earnings per share?
Immunome earned $-2.43 per diluted share in fiscal 2025, compared with $-4.73 a year earlier.
When will Immunome report its next earnings?
Immunome is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes.
When does Immunome's fiscal year end?
Immunome's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 3, 2026.